Androgen receptor therapeutic modulation

Kim, J., Wu, D., Hwang, D.J., Miller, D.D. and Dalton, J.T. (2005) The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromefhyl-phenylj-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. The Journal of Pharmacology and Experimental Therapeutics, 315, 230-239. 

D. D. and Dalton, J.T. (2005) A selective androgen receptor modulator for hormonal male contraception. The Journal of Pharmacology and Experimental Therapeutics, 312, 546-553. 

Mohler, M.L., Nair, V.A., Hwang, D.J., Rakov, I.M., Patil, R. and Miller, D.D. (2005) Nonsteroidal tissue selective androgen receptor modulators a promising class of clinical candidates. Expert Opinion on Therapeutic Patents, 15, 1565-1585. 

Discovery and therapeutic promise of selective androgen receptor modulators. Molecular Interventions, 5, 173-188. 

CadUla, R., and Turnbull, P. (2006) Selective androgen receptor modulators in drug discovery Medicinal chemistry and therapeutic potential. Current Topics in Medicinal Chemistry, 6,245-270. 

Gao, W., and Dalton, J.T. (2007) Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discovery Today, 12,241-248. 

Chen, F., Rodan, G.A., and Schmidt, A. (2002) Development of selective androgen receptor modulators and their therapeutic applications. National Journal ofAndrology, 8,162-168. 

---